Pyridoxine (Tablets, Solution) Instructions for Use
ATC Code
A11HA02 (Pyridoxine (vitamin B6))
Active Substance
Pyridoxine (Rec.INN registered by WHO)
Clinical-Pharmacological Group
B vitamin
Pharmacotherapeutic Group
Vitamins; other vitamin preparations
Pharmacological Action
Vitamin B6. It plays an important role in metabolism; it is necessary for the normal functioning of the central and peripheral nervous system.
In its phosphorylated form, Pyridoxine is a coenzyme for a large number of enzymes acting on the non-oxidative metabolism of amino acids (including decarboxylation and transamination processes).
Pyridoxine is involved in the metabolism of tryptophan, methionine, cysteine, glutamic acid, and other amino acids.
It plays an important role in histamine metabolism. It helps to normalize lipid metabolism.
Pharmacokinetics
It is metabolized in the liver to form pharmacologically active metabolites (pyridoxal phosphate and pyridoxamine phosphate).
Pyridoxal phosphate is 90% bound to plasma proteins. It is distributed mainly in the liver, and to a lesser extent in muscles and the CNS.
It crosses the placenta and is excreted in breast milk. The elimination half-life (T1/2) is 15-20 days.
It is excreted by the kidneys (with intravenous administration, 2% is excreted in bile) and also by hemodialysis.
Indications
For oral administration: treatment of hypo- and avitaminosis B6. As part of complex therapy for diseases of the nervous system ( neuralgia, Ménière’s syndrome); in dermatology ( dermatitis, including atopic and seborrheic; herpes zoster, neurodermatitis, psoriasis, exudative diathesis); sideroblastic anemia; acute and chronic hepatitis.
For parenteral administration: hypo- and avitaminosis B6; congenital pyridoxine-dependent convulsive syndrome in newborns; prevention and treatment of neurotoxicity caused by isoniazid and other derivatives of isonicotinic acid hydrazide. As part of complex therapy for diseases of the nervous system: parkinsonism, central or peripheral paralysis, Little’s disease, Ménière’s disease and syndrome, seasickness and airsickness, radiculitis, neuralgia, neuritis.
ICD codes
| ICD-10 code | Indication |
| B02 | Zoster [herpes zoster] |
| B15 | Acute hepatitis A |
| B16 | Acute hepatitis B |
| B17.1 | Acute hepatitis C |
| B18.0 | Chronic viral hepatitis B with delta-agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| B18.2 | Chronic viral hepatitis C |
| D64.3 | Other sideroblastic anemias |
| E53.1 | Pyridoxine deficiency |
| G20 | Parkinson's disease |
| G21 | Secondary parkinsonism |
| G80 | Cerebral palsy |
| G81 | Hemiplegia |
| G82 | Paraplegia and tetraplegia |
| G83 | Other paralytic syndromes |
| H81.0 | Ménière's disease |
| K73 | Chronic hepatitis, not elsewhere classified |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L21 | Seborrheic dermatitis |
| L28.0 | Lichen simplex chronicus (circumscribed neurodermatitis) |
| L40 | Psoriasis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M79.2 | Neuralgia and neuritis, unspecified |
| P90 | Convulsions of newborn |
| T75.3 | Motion sickness |
| Y41.1 | Antimycobacterial drugs |
| ICD-11 code | Indication |
| 1E50.0 | Acute hepatitis A |
| 1E50.1 | Acute hepatitis B |
| 1E50.2 | Acute hepatitis C |
| 1E51.0Z | Chronic hepatitis B, unspecified |
| 1E51.1 | Chronic viral hepatitis C |
| 1E51.2 | Chronic hepatitis D |
| 1E91.Z | Herpes zoster, unspecified |
| 3A72.Z | Sideroblastic anemia, unspecified |
| 5B5D | Vitamin B6 deficiency |
| 8A00.0Z | Parkinson's disease, unspecified |
| 8A00.2Z | Secondary parkinsonism, unspecified |
| 8A0Y | Other specified movement disorders |
| 8B93.Z | Radiculopathy, unspecified |
| 8D2Z | Cerebral palsy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| 9A06.70 | Atopic eczema of the eyelids |
| AB31.0 | Ménière's disease |
| DB97.2 | Chronic hepatitis, not elsewhere classified |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA81.Z | Seborrheic dermatitis, unspecified |
| EA83.00 | Lichen simplex of vulva |
| EA83.01 | Lichen simplex of male genital organs |
| EA83.02 | Lichen simplex of perianal area |
| EA83.0Z | Lichen simplex of unspecified location |
| EA85.20 | Atopic hand eczema |
| EA90.Z | Psoriasis, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| KB06 | Neonatal convulsions |
| LD90.1 | Early-onset parkinsonism-mental retardation |
| MB50.Z | Tetraplegia, unspecified |
| MB53.0 | Alternating hemiplegia |
| MB53.Z | Hemiplegia, unspecified |
| MB56 | Paraplegia |
| MB5Z | Paralytic symptoms, unspecified |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| NF08.3 | Motion sickness |
| PL00 | Drugs, medicaments or biological substances causing injury or harm in therapeutic use |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets, Solution
It is used orally and parenterally (subcutaneously, intramuscularly, or intravenously).
The dose, method and scheme of application, and duration of therapy are determined individually, depending on the indications, clinical situation, patient’s age, and the dosage form used; when conducting combination therapy, the doses of pyridoxine also depend on the components of the combination used.
Adverse Reactions
In some cases: allergic reactions, hypersecretion of hydrochloric acid.
Possible: allergic reactions, increased acidity of gastric juice, pain in the epigastric region, sensation of pressure in the extremities – “stocking and glove” symptom, decreased lactation; with rapid administration – convulsions.
Contraindications
Hypersensitivity to pyridoxine; pediatric age – depending on the dosage form.
With caution: gastric and duodenal ulcer (due to possible increase in gastric acidity), coronary artery disease, severe liver damage.
Use in Pregnancy and Lactation
During pregnancy, it should be used only after consultation with a doctor, in cases where the intended benefit to the mother outweighs the potential risk to the fetus.
If it is necessary to use during lactation, the issue of discontinuing breastfeeding should be decided.
Long-term use of pyridoxine in high doses during pregnancy and breastfeeding may lead to the development of pyridoxine dependence in children. It is not recommended to exceed the physiological requirement norms for pyridoxine during pregnancy (2 mg/day).
Use in Hepatic Impairment
It should be used with caution in severe liver damage.
Pediatric Use
It can be used in children of appropriate age categories according to indications, in recommended doses and dosage forms. It is necessary to strictly follow the instructions in the pyridoxine drug leaflets regarding contraindications for the use of specific pyridoxine dosage forms in children of different ages.
Special Precautions
In severe liver damage, Pyridoxine in high doses may cause deterioration of its function.
When determining urobilinogen using Ehrlich’s reagent, Pyridoxine may distort the results.
Drug Interactions
The physiological function of vitamins B1 and B6 is to potentiate each other’s action, manifested in a positive effect on the nervous, muscular, and cardiovascular systems.
With simultaneous use with hormonal contraceptives, an increase in the concentration of pyridoxine in blood plasma is possible.
With simultaneous use, Pyridoxine potentiates the action of diuretics.
With simultaneous use with levodopa, the effects of levodopa are reduced or completely inhibited.
With simultaneous use with isonicotinyl hydrazide, penicillamine, cycloserine, a decrease in the effectiveness of pyridoxine is possible.
With simultaneous use with phenytoin, phenobarbital, a decrease in the plasma concentrations of phenytoin and phenobarbital is possible.
Pyridoxine can be used in combination with cardiac glycosides ( Pyridoxine promotes increased synthesis of contractile proteins in the myocardium), with glutamic acid, and with potassium and magnesium asparaginate.
Pyridoxine prevents or reduces toxic manifestations, including liver damage, observed when using isoniazid and other anti-tuberculosis drugs.
Simultaneous use of pyridoxine with cycloserine, ethionamide, hydralazine, azathioprine, chlorambucil, corticotropin, cyclophosphamide, cyclosporine, mercaptopurine, isoniazid, penicillamine may cause anemia and neuropathy.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Injection solution 50 mg/1 ml: amp. 5 or 10 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for injection transparent, colorless or slightly yellowish.
| 1 ml | |
| Pyridoxine hydrochloride | 50 mg |
Excipients: water for injections – up to 1 ml.
1 ml – ampoules (5) – contour cell packaging (1) – cardboard packs.
1 ml – ampoules (5) – contour cell packaging (2) – cardboard packs.
1 ml – ampoules (5) – cardboard trays (1) – cardboard packs.
1 ml – ampoules (5) – cardboard trays (2) – cardboard packs.
Injection solution 10 mg/1 ml: amp. 1 or 2 ml, 10 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 10 mg/1 ml: amp. 1 or 2 ml, 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 10 mg |
1 ml – ampoules (10) – cardboard packs.
2 ml – ampoules (10) – cardboard packs.
Injection solution 50 mg/1 ml: amp. 1 or 2 ml, 10 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 1 or 2 ml, 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – cardboard packs.
2 ml – ampoules (10) – cardboard packs.
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – cardboard packs.
Solution for injection 10 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Borisov Plant Of Medical Preparations, PJSC (Republic Of Belarus)
Dosage Form
| Pyridoxine | Solution for injection 10 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 10 mg |
1 ml – ampoules (10) – cardboard packs.
Solution for injection 10 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Solution for injection 10 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 10 mg |
1 ml – ampoules (10) – cardboard packs.
1 ml – ampoules (5) – contour plastic packaging (2) – cardboard packs.
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – cardboard packs.
1 ml – ampoules (5) – contour plastic packaging (2) – cardboard packs.
Solution for injection 20 mg/2 ml: amp. 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Solution for injection 20 mg/2 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 10 mg | 20 mg |
2 ml – ampoules (10) – cardboard packs.
2 ml – ampoules (5) – contour plastic packaging (2) – cardboard packs.
Injection solution 100 mg/2 ml: amp. 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 100 mg/2 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 50 mg | 100 mg |
2 ml – ampoules (10) – carton packs.
2 ml – ampoules (5) – plastic contour packs (2) – carton packs.
Injection solution 50 mg/1 ml: amp. 1 10 pcs.
Marketing Authorization Holder
Lvivdialek State Production Association Ukrmedprom (Ukraine)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 1 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
1 ml – ampoules (5) – contour cell packs (2) – carton packs.
Injection solution 50 mg/1 ml: amp. 5, 10 or 20 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (5) – plastic contour packs (1) – carton packs.
1 ml – ampoules (5) – plastic contour packs (2) – carton packs.
1 ml – ampoules (10) – plastic contour packs (2) – carton packs.
1 ml – ampoules (10) – plastic contour packs (1) – carton packs.
Injection solution 100 mg/2 ml: amp. 5, 10 or 20 pcs.
Marketing Authorization Holder
Novosibkhimpharm, JSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 100 mg/2 ml: amp. 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 50 mg | 100 mg |
2 ml – ampoules (5) – plastic contour packs (1) – carton packs.
2 ml – ampoules (5) – plastic contour packs (2) – carton packs.
2 ml – ampoules (10) – plastic contour packs (2) – carton packs.
2 ml – ampoules (10) – plastic contour packs (1) – carton packs.
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Statusfarm LLC (Russia)
Manufactured By
Yerevan Chemical And Pharmaceutical Firm, OJSC (Armenia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
Injection solution as a transparent, colorless or yellowish liquid.
| 1 ml | |
| Pyridoxine hydrochloride | 50 mg |
Excipients: water for injections – up to 1 ml.
1 ml – glass ampoules (10) – carton boxes.
Solution for injection 10 mg/1 ml: amp. 10, 150, or 200 pcs.
Marketing Authorization Holder
Pharmstandard-Ufimsky Vitaminny Zavod OJSC (Russia)
Dosage Form
| Pyridoxine | Solution for injection 10 mg/1 ml: amp. 10, 150, or 200 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 10 mg |
1 ml – ampoules (10) – carton packs.
1 ml – ampoules (150) – carton boxes.
1 ml – ampoules (200) – carton boxes.
Injection solution 20 mg/2 ml: amp. 10, 150, or 200 pcs.
Marketing Authorization Holder
Pharmstandard-Ufimsky Vitaminny Zavod OJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 20 mg/2 ml: amp. 10, 150, or 200 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 10 mg | 20 mg |
2 ml – ampoules (10) – carton packs.
2 ml – ampoules (150) – carton packs.
2 ml – ampoules (200) – carton packs.
Injection solution 50 mg/1 ml: amp. 10, 150 or 200 pcs.
Marketing Authorization Holder
Pharmstandard-Ufimsky Vitaminny Zavod OJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 10, 150 or 200 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
1 ml – ampoules (150) – carton packs.
1 ml – ampoules (200) – carton packs.
Injection solution 100 mg/2 ml: amp. 10, 150 or 200 pcs.
Marketing Authorization Holder
Pharmstandard-Ufimsky Vitaminny Zavod OJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 100 mg/2 ml: amp. 10, 150 or 200 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 50 mg | 100 mg |
2 ml – ampoules (10) – carton packs.
2 ml – ampoules (150) – carton packs.
2 ml – ampoules (200) – carton packs.
Injection solution 50 mg/1 ml: amp. 3, 5, 10 or 20 pcs.
Marketing Authorization Holder
Mir Chemical and Pharmaceutical Concern, LLC (Russia)
Manufactured By
NPC Eskom, PJSC (Russia)
Dosage Form
| Pyridoxine | Injection solution 50 mg/1 ml: amp. 3, 5, 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Injection solution as a transparent, colorless or slightly yellowish liquid.
| 1 ml | |
| Pyridoxine hydrochloride | 50 mg |
Excipients: water for injections – up to 1 ml.
1 ml – colorless glass ampoules (3 or 5) – contour cell packs (1) – carton packs.
1 ml – colorless glass ampoules (5) – contour cell packs (2 or 4) – carton packs.
1 ml – colorless glass ampoules (10) – contour cell packs (1 or 2) – carton packs.
1 ml – colorless glass ampoules (5) – contour cell packs (10 or 20) – carton packs (for hospitals).
1 ml – colorless glass ampoules (10) – contour cell packs (5 or 10) – carton packs (for hospitals).
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
| Pyridoxine Bufus | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
Injection solution 100 mg/2 ml: amp. 10 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
| Pyridoxine Bufus | Injection solution 100 mg/2 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml | 1 amp. |
| Pyridoxine hydrochloride | 50 mg | 100 mg |
2 ml – ampoules (10) – carton packs.
Tablets 10 mg: 10, 20, 30, 40, 50, 100, 150, 200, 250, or 500 pcs.
Marketing Authorization Holder
Ozon, LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Or
Ozon Pharm, LLC (Russia)
Dosage Form
| Pyridoxine hydrochloride | Tablets 10 mg: 10, 20, 30, 40, 50, 100, 150, 200, 250, or 500 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score.
| 1 tab. | |
| Pyridoxine hydrochloride | 10 mg |
Excipients: dextrose monohydrate (glucose monohydrate) – 77.5 mg, microcrystalline cellulose (MCC-102) – 9.5 mg, povidone K17 – 1.5 mg, calcium stearate – 1 mg, colloidal silicon dioxide – 0.5 mg.
10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – contour cell packs (3) – carton packs.
10 pcs. – contour cell packs (4) – carton packs.
10 pcs. – contour cell packs (5) – carton packs.
10 pcs. – contour cell packs (10) – carton packs.
50 pcs. – contour cell packs (1) – carton packs.
50 pcs. – contour cell packs (2) – carton packs.
50 pcs. – contour cell packs (3) – carton packs.
50 pcs. – contour cell packs (4) – carton packs.
50 pcs. – contour cell packs (5) – carton packs.
50 pcs. – contour cell packs (10) – carton packs.
Injection solution 50 mg/1 ml: amp. 1 ml 10 pcs.
Marketing Authorization Holder
Grotex, LLC (Russia)
Dosage Form
| Pyridoxine-SOLOpharm | Injection solution 50 mg/1 ml: amp. 1 ml 10 pcs. |
Dosage Form, Packaging, and Composition
Injection solution as a transparent, colorless or colored liquid.
| 1 ml | |
| Pyridoxine hydrochloride | 50 mg |
Excipients: water for injections – up to 1 ml.
1 ml – glass ampoules (5) – contour cell packs (2) – carton packs.
1 ml – glass ampoules (10) – contour cell packs (1) – carton packs.
1 ml – glass ampoules (5) – cardboard forms (2) – carton packs.
1 ml – glass ampoules (10) – cardboard forms (1) – carton packs.
Injection solution 50 mg/1 ml: amp. 10 pcs.
Marketing Authorization Holder
Vial, LLC (Russia)
Manufactured By
CSPC Ouyi Pharmaceutical, Co. Ltd. (China)
Dosage Form
| Pyridoxine-Vial | Injection solution 50 mg/1 ml: amp. 10 pcs. |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
Solution for injection 50 mg/1 ml: amp. 10 or 100 pcs. (packaged by Ozon LLC)
Marketing Authorization Holder
Vial, LLC (Russia)
Manufactured By
CSPC Ouyi Pharmaceutical, Co. Ltd. (China)
Or
Ozon, LLC (Russia)
Dosage Form
| Pyridoxine-Vial | Solution for injection 50 mg/1 ml: amp. 10 or 100 pcs. (packaged by Ozon LLC) |
Dosage Form, Packaging, and Composition
| Injection solution | 1 ml |
| Pyridoxine hydrochloride | 50 mg |
1 ml – ampoules (10) – carton packs.
1 ml – ampoules (10) – plastic contour packs (10) – carton packs.
Actovegin pills 200mg, 50pcs
Ingavirin capsules 90mg, 10pcs
Daivobet, ointment, 30g
Noopept, pills 10mg, 50pcs
OKI, sachets 80mg 2g, 12pcs
Fenotropil pills 100mg, 60pcs
Picamilon pills 50mg, 60pcs
Cortexin, 10mg, 5ml, 10pcs
Kagocel pills 12mg, 30pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, ointment, 30g
Cavinton Comfort, dispersible pills 10mg 90pcs
Arbidol, capsules 100mg, 40pcs
Nootropil pills 800mg, 30pcs 